Ann Siehoff

This inventor holds 4 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents. Top assignees: Lonza Cologne Gmbh, Lonza Walkersville, Inc., Octane Biotech Inc.. Active years: 2022-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ann Siehoff. Retrieved from https://idiyas.com/inventor/ann-siehoff

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 10.0

ph-index = 2

Forward Citations = 49(Granted Patents)

Company Filing History:

Lonza Walkersville, Inc.

where one patent can have more than one assignee

Years Active: 2022-2023

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11827902 - End-to-end cell therapy automation (2023-11-28),

2. 11781113 - End-to-end cell therapy automation (2023-10-10),

3. 11447745 - End-to-end cell therapy automation (2022-09-20),

4. 11371018 - End-to-end cell therapy automation (2022-06-28),

Title: Ann Siehoff - Innovator in Cell Therapy Automation

Introduction

Ann Siehoff is a prominent inventor based in Cologne, Germany. She has made significant contributions to the field of cell therapy automation, holding a total of four patents. Her work focuses on the development of automated methods for producing genetically modified immune cells, which are crucial for advancing medical treatments.

Latest Patents

Among her latest patents is the innovative "End-to-end cell therapy automation." This patent provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system. This advancement is pivotal in streamlining the production process and enhancing the efficiency of cell therapies.

Career Highlights

Throughout her career, Ann has worked with notable companies such as Lonza Walkersville, Inc. and Lonza Cologne GmbH. Her experience in these organizations has allowed her to develop and refine her expertise in cell therapy automation, contributing to her success as an inventor.

Collaborations

Ann has collaborated with esteemed colleagues, including Yaling Shi and Erika McAfee. These partnerships have fostered innovation and have been instrumental in her research and development efforts.

Conclusion

Ann Siehoff's contributions to cell therapy automation exemplify her dedication to advancing medical technology. Her innovative patents and collaborative efforts position her as a key figure in the field, paving the way for future advancements in cell therapy.

Profile summary based on public USPTO records.